Ausgabe 5/2005
Inhalt (9 Artikel)
Allopurinol or Oxypurinol in Heart Failure Therapy – a Promising New Development or End of Story?
Ariel J. Reyes, William P. Leary
Cardioprotective-Mimetics Reduce Myocardial Infarct Size in Animals Resistant to Ischemic Preconditioning
Richard J. Gumina, Jo El Schultz, Jeanine Moore, Norbert Beier, Pierre Schelling, Garrett J. Gross
Vasopeptidase Inhibition Peri- and Post-MI in Zucker Insulin Resistant Rats: Effect on MI Size, Arrhythmias, Remodeling, Function and Fetal Gene Expression
Nathalie Lapointe, Quang Trinh Nguyen, Jean-François Desjardins, Jim Tsoporis, François Marcotte, Ali Pourdjabbar, Thomas G. Parker, Gordon Moe, Albert Adam, Jean-Lucien Rouleau
Chronic Erythropoietin Treatment Limits Infarct-size in the Myocardium in Vitro
Anthony John Bullard, Derek Miles Yellon
The Sulfonylurea Glipizide Does Not Inhibit Ischemic Preconditioning in Anesthetized Rabbits
David M. Flynn, Andrew H. Smith, Judith L. Treadway, Carolyn B. Levy, Walter C. Soeller, Wayne A. Boettner, Peter Wisniecki, David R. Plowchalk, Steve S. Gernhardt, W. Ross Tracey, Delvin R. Knight
Carvedilol Exerts More Potent Antiadrenergic Effect than Metoprolol in Heart Failure
Takashi Kohno, Tsutomu Yoshikawa, Akihiro Yoshizawa, Iwao Nakamura, Toshihisa Anzai, Toru Satoh, Satoshi Ogawa
Economic Impact of Hyperhomocysteinemia in Switzerland
Thomas D. Szucs, Andreas Käser, Walter F. Riesen
Intracranial Hemorrhages Associated with Intravenous Platelet Glycoprotein IIB/IIIA Receptor Inhibitors in the United States
Adnan I. Qureshi, M. S. Hussain, Abu Nasar, Jawad F. Kirmani, Afshin A. Divani, Shafiudin Ahmed, M. Fareed K. Suri